Curasight
Curasight to present at Dansk Aktionærforening InvestorDagen
REG
Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating cancer, and its view on the newly published peer-reviewed data in the journal EJNMMI Research from the Phase II uTRACE trial in brain cancer and its impact for the Curasight clinical development strategy.
The Dansk Aktionærforening InvestorDagen presentation will be recorded 14:05 - 14:30 (CET), Monday 11 November 2024.
Should you be unable to attend the event, a link to the presentation will be made available on Curasight's website, after the event.
For more information - please click here
| Datum | 2024-11-08, kl 10:42 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!